🔆 Beacon

← Search all trials on Beacon

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Recruiting now Phase 4 NCT05548283

Run by Chris Goss · for 6 and older · All sexes

What this study is about

The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonary exacerbation: * Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two different types of antibiotics (tobramycin and β-lactams)? * Is taking one type of antibiotic just as good as taking two types?

Who can join (things the study team will check)

✅ You may be able to join if…

🚫 You may not be able to join if…

Where this trial is running

+ 48 more sites.

Who to contact

Rachael Buckingham, BS · 206-884-7517 · Rachael.buckingham@seattlechildrens.org

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05548283.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.